Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies
Kirsten C. Morley, Christina J. Perry, Joshua Watt, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1291-1303
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Baclofen for alcohol use disorder
Roberta Agabio, Rosella Saulle, Susanne Rösner, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 26
Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial
Kirsten C. Morley, Henry R. Kranzler, Natasha Luquin, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 5, pp. 403-411
Closed Access | Times Cited: 7
Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders
Michael P. Bremmer, Christian S. Hendershot
Journal of Studies on Alcohol and Drugs (2023)
Closed Access | Times Cited: 14
The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
Stephan C. Tap
Addiction Biology (2024) Vol. 29, Iss. 4
Open Access | Times Cited: 5
Identification and Treatment of Alcohol Use Disorder
Paul Haber
New England Journal of Medicine (2025) Vol. 392, Iss. 3, pp. 258-266
Closed Access
Cannabidiol attenuates precuneus activation during appetitive cue exposure in individuals with alcohol use disorder
Tristan Hurzeler, Warren Logge, Joshua Watt, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Open Access
N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial
Kirsten C. Morley, Siena Peruch, Claire Adams, et al.
Alcohol and Alcoholism (2023) Vol. 58, Iss. 5, pp. 553-560
Closed Access | Times Cited: 12
Astrocytic GABAergic Regulation in Alcohol Use and Major Depressive Disorders
Dina Ali, H. Mokdad Ali, Matthew R. Lopez, et al.
Cells (2024) Vol. 13, Iss. 4, pp. 318-318
Open Access | Times Cited: 4
The neurobehavioural effects of cannabidiol in alcohol use disorder: study protocol for a double-blind, randomised, cross over, placebo-controlled trial
Tristan Hurzeler, Warren Logge, Joshua Watt, et al.
Contemporary Clinical Trials Communications (2024) Vol. 41, pp. 101341-101341
Open Access | Times Cited: 4
Central markers of neuroinflammation in alcohol use disorder: A meta‐analysis of neuroimaging, cerebral spinal fluid, and postmortem studies
Claire Adams, Nina Perry, James H. Conigrave, et al.
Alcohol Clinical and Experimental Research (2023) Vol. 47, Iss. 2, pp. 197-208
Closed Access | Times Cited: 9
Neuroimaging studies of cannabidiol and potential neurobiological mechanisms relevant for alcohol use disorders: a systematic review
Tristan Hurzeler, Joshua Watt, Warren Logge, et al.
Journal of Cannabis Research (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
GHSR blockade, but not reduction of peripherally circulating ghrelin via β1-adrenergic receptor antagonism, decreases binge-like alcohol drinking in mice
Rani Richardson, Lindsay A Kryszak, Janaina C. M. Vendruscolo, et al.
Molecular Psychiatry (2024)
Open Access | Times Cited: 2
Tph2 Gene Expression Defines Ethanol Drinking Behavior in Mice
Magdalena Zaniewska, Valentina Mosienko, Michael Bäder, et al.
Cells (2022) Vol. 11, Iss. 5, pp. 874-874
Open Access | Times Cited: 9
A Cognitive Pathway to Persistent, Maladaptive Choice
Gavan P. McNally, Philip Jean-Richard-Dit-Bressel
European Addiction Research (2024) Vol. 30, Iss. 4, pp. 233-242
Open Access | Times Cited: 1
High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study
Kirsten C. Morley, Warren Logge, I.S. Fraser, et al.
European Neuropsychopharmacology (2021) Vol. 46, pp. 28-36
Closed Access | Times Cited: 11
The effects of N-acetyl cysteine on intrinsic functional connectivity and neural alcohol cue reactivity in treatment-seeking individuals with alcohol use disorder: a preliminary study
Warren Logge, Paul Haber, Tristan Hurzeler, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 1
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
Ruth Asch, Ansel T. Hillmer, Stephen R. Baldassarri, et al.
International review of neurobiology (2022), pp. 265-310
Closed Access | Times Cited: 6
Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia
Luis Santos-Molina, Alexa Herrerias, Charles N. Zawatsky, et al.
Molecules (2021) Vol. 26, Iss. 16, pp. 5089-5089
Open Access | Times Cited: 7
Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence
Kirsten C. Morley, Eva Louie, Tristan Hurzeler, et al.
Frontiers in Global Women s Health (2022) Vol. 3
Open Access | Times Cited: 5
Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time during baclofen treatment for alcohol dependence
Warren Logge, Andrew Baillie, Paul Haber, et al.
Addictive Behaviors (2022) Vol. 136, pp. 107462-107462
Closed Access | Times Cited: 5
Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder
Benjamin Higginbotham, Joahna Kevin Perez, Eva Louie, et al.
Australian & New Zealand Journal of Psychiatry (2023) Vol. 58, Iss. 2, pp. 117-133
Open Access | Times Cited: 2
Dihydromyricetin Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line: Role of GABAA Receptor
Bruk Getachew, Antonei B. Csòka, Yousef Tizabi
Neurotoxicity Research (2022) Vol. 40, Iss. 3, pp. 892-899
Closed Access | Times Cited: 4
Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact
Kirsten C. Morley
Addiction (2021) Vol. 116, Iss. 11, pp. 3027-3028
Open Access | Times Cited: 5
The effectiveness of the original anticonvulsant Galodif® — a GABAA receptor modulator for alcohol withdrawal syndrome
T. Shushpanova, А.И. Мандель, Н. А. Бохан, et al.
Reviews on Clinical Pharmacology and Drug Therapy (2024) Vol. 21, Iss. 4, pp. 373-389
Closed Access
Central Amygdala Neuroimmune Signaling in Alcohol Use Disorder
Mariam Melkumyan, Patrick A. Randall, Yuval Silberman
Addiction Neuroscience (2024), pp. 100194-100194
Open Access
Page 1 - Next Page

Scroll to top